Loading...
01/09 23:13
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents mixed signals: strong product inspection growth and raised forecasts contrast with lower EPS guidance and declining free cash flow. Management's confidence in offsetting tariff impacts and stable demand in China are positives, but uncertainties in process analytics and the replacement cycle remain. The lack of detailed guidance on key areas and cautious outlook for Europe and China suggest a neutral sentiment, with limited short-term stock movement expected.
Sales Sales in the quarter were $983 million, which represented an increase in local currency of 2%. On a U.S. dollar reported basis, sales increased 4%. Local currency sales increased 3% in the Americas, were flat in Europe, and increased 3% in Asia/Rest of the World. Local currency sales in China declined 2% during the quarter.
Gross Margin Gross margin was 59.0% in the quarter, a decrease of 70 basis points. Positive price realization and benefits from the SternDrive program were offset by incremental tariff costs and lower volume.
R&D Expenses R&D amounted to $49.3 million in the quarter, which is a 3% increase in local currency over the prior year.
SG&A Expenses SG&A amounted to $247.3 million, a 2% increase in local currency over the prior year.
Adjusted Operating Profit Adjusted operating profit amounted to $283.3 million in the quarter and was flat versus the prior year. Adjusted operating margin was 28.8%, a decrease of 120 basis points versus the prior year. The gross impact of tariffs reduced the operating margin by approximately 130 basis points.
Adjusted EPS Adjusted EPS for the quarter was $10.09, a 5% increase over the prior year. Incremental tariff costs were a gross headwind of 5% and a net headwind of about 1.5% in the quarter.
Reported EPS On a reported basis in the quarter, EPS was $9.76 as compared to $10.37 in the prior year, which included a discrete tax benefit of $1.07. Reported EPS in the quarter included $0.24 of purchased intangible amortization, $0.14 of restructuring costs, and a $0.05 tax benefit related to the timing of stock option exercises.
Adjusted Free Cash Flow Adjusted free cash flow amounted to $409 million for the first 6 months, a 3% decrease on a per share basis due to lower earnings and higher bonus payments related to last year's performance.
Bioprocessing-related sales: Remain strong with a healthy outlook for the year. Unique solutions offering for bioproduction across entire workflow.
Process Analytics innovations: Introduced digital analytical sensors with strong digital signals and single-use sensors covering a wide range of parameters.
Onshoring investments: Portfolio positioned to benefit from onshoring investments over the coming years, with focus on identifying new project opportunities.
Geographic performance: Strong growth in Americas due to industrial and product inspection. Europe sales flat, and Asia showed strong growth in Southeast Asia but soft conditions in China.
Tariff mitigation: Proactive efforts to offset incremental costs and increase global supply chain resiliency.
Service business growth: Grew 4% in the quarter and 5% year-to-date, with optimism for good growth in the second half of the year.
Onshoring and regional supply chains: Significant growth opportunities from onshoring and regional supply chain development, especially in the U.S.
Replacement demand: Pent-up demand for replacing aging equipment due to deferred investments, expected to increase as business environment stabilizes.
Global Trade Disputes and Tariffs: The U.S. administration announced a significant increase in tariffs on imports from Switzerland to 39%, which is expected to negatively impact EPS guidance for 2025 by approximately $0.40. Incremental tariff costs are estimated at $95 million annually, creating a gross headwind of 5% to adjusted EPS. These tariffs and retaliatory measures from other countries add uncertainty and financial strain.
Market Conditions and Customer Investment Caution: Challenging market conditions and cautious customer investments due to global trade disputes and governmental policy uncertainties are impacting growth. This is particularly evident in sectors like academia, biotech, and chemical industries, which are experiencing softer demand.
China Market Conditions: Underlying market conditions in China remain soft, with no expected improvement in the second half of 2025. This impacts sales growth and creates uncertainty in one of the company's key markets.
Supply Chain and Tariff Mitigation: Incremental tariff costs and the need for mitigation actions are straining the supply chain. While the company is implementing measures to offset these costs, the dynamic nature of tariffs and geopolitical tensions adds complexity and risk to supply chain operations.
Operating Margin and Cost Pressures: Operating margin decreased by 120 basis points in Q2 2025, with gross margin also declining due to incremental tariff costs and lower volume. These pressures are expected to persist, impacting profitability.
Deferred Equipment Replacement: Trade and policy uncertainties have delayed replacement cycles for lab equipment, creating pent-up demand but also impacting current sales and revenue.
Foreign Currency Impact: Foreign currency fluctuations are a slight headwind to adjusted EPS in 2025, adding another layer of financial uncertainty.
Revenue Growth: For Q3 2025, local currency sales are expected to grow approximately 3% to 4%. For the full year 2025, local currency sales growth is forecasted at 1% to 2%, or 2.5% to 3.5% excluding shipping delays.
Adjusted EPS: For Q3 2025, adjusted EPS is expected to range between $10.55 and $10.75, reflecting a growth rate of 3% to 5%. For the full year 2025, adjusted EPS is projected to be between $41.70 and $42.20, reflecting growth of 1% to 3%, or 5% to 7% excluding shipping delays.
Tariff Impact: Incremental global tariff costs are estimated at approximately $95 million annually, with mitigation actions expected to fully offset these costs by 2026. The recent increase in U.S. tariffs on Swiss imports to 39% is expected to negatively impact 2025 adjusted EPS by approximately $0.40.
Operating Margin: Operating margin for Q3 2025 is expected to decrease by approximately 130 basis points at the midpoint of the range. For the full year 2025, operating margin is expected to decline modestly, excluding the net impacts of tariffs and prior year shipping delays.
Free Cash Flow: Free cash flow for 2025 is expected to be approximately $860 million.
Market Conditions: Market conditions are expected to remain challenging in the second half of 2025, with no assumed improvement. However, higher pricing compared to the first half of the year is expected to provide some benefit.
Growth Opportunities: The company anticipates benefiting from onshoring investments, increased demand for automation and productivity solutions, and replacement of aging equipment as market conditions stabilize. Growth opportunities are also expected in biopharma, e-mobility, renewable energy, and quality control requirements in China.
Share Repurchase: Share repurchases are expected to be approximately $875 million for the year 2025.
The earnings call summary presents a mixed picture. Financial performance shows modest growth, with challenges from tariffs and market conditions. Product development and business updates are positive, especially in bioprocessing. Market strategy is cautious due to global uncertainties. Expenses indicate some margin pressure. Shareholder returns are not prominently discussed. The Q&A reveals cautious guidance for 2026 and strategies to mitigate tariffs. Overall, the sentiment is balanced, with no strong catalysts for a significant stock price move. The neutral rating reflects these mixed signals.
The earnings call presents mixed signals: strong product inspection growth and raised forecasts contrast with lower EPS guidance and declining free cash flow. Management's confidence in offsetting tariff impacts and stable demand in China are positives, but uncertainties in process analytics and the replacement cycle remain. The lack of detailed guidance on key areas and cautious outlook for Europe and China suggest a neutral sentiment, with limited short-term stock movement expected.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
